JP Patent

JP2024522189A — Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Assigned to Incyte Corp · Expires 2024-06-11 · 2y expired

What this patent protects

本開示は、ＦＧＦＲ酵素の阻害剤であり、ＦＧＦＲ関連疾患（がんなど）の治療に有用な三環式ヘテロ環及びその医薬組成物に関する。

USPTO Abstract

本開示は、ＦＧＦＲ酵素の阻害剤であり、ＦＧＦＲ関連疾患（がんなど）の治療に有用な三環式ヘテロ環及びその医薬組成物に関する。

Drugs covered by this patent

Pemazyre (PEMIGATINIB) · Incyte Corp

Patent Metadata

Patent number: JP2024522189A
Jurisdiction: JP
Classification: —
Expires: 2024-06-11
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.